INSPIRED BY PATIENTS
DRIVEN BY SCIENCE

J.P. Morgan Healthcare Conference

Clay Siegall, Ph.D.
President and Chief Executive Officer

January 10, 2022

Forward-Looking Statements

Certain of the statements made in this presentation are forward looking, such as those, among others, relating to the Company's outlook, including anticipated revenues, costs and expenses, and its potential for growth; the Company's potential to achieve the noted development and regulatory milestones in 2022 and in future periods, if at all; anticipated activities related to the Company's planned and ongoing clinical trials; the opportunities for, and the therapeutic and commercial potential of, ADCETRIS®, PADCEV®, TUKYSA®, TIVDAK®, ladiratuzumab vedotin, disitamab vedotin and the Company's other product candidates and those of its licensees and collaborators; the potential for the Company's products to receive additional global regulatory approvals or label expansions; the Company's pipeline; as well as other statements that are not historical fact. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include without limitation: the risks that the Company's ADCETRIS, PADCEV, TUKYSA and TIVDAK net sales, revenues, expenses, costs, and financial guidance may not be as expected; risks and uncertainties associated with maintaining or increasing sales of ADCETRIS, PADCEV, TUKYSA and TIVDAK due to competition, unexpected adverse events, regulatory action, government pricing and/or reimbursement actions, market adoption by physicians, impacts associated with COVID-19 or other factors; the risks that the Company or its collaborators may be delayed or unsuccessful in planned clinical trial initiations, enrollment in and conduct of clinical trials, obtaining data from clinical trials, planned regulatory submissions, and regulatory approvals in the U.S. and in other countries in each case for a variety of reasons including the difficulty and uncertainty of pharmaceutical product development, negative or disappointing clinical trial results, unexpected adverse events or regulatory actions and the inherent uncertainty associated with the regulatory approval process; and risks related to the duration and severity of the COVID-19 pandemic and resulting global economic, financial and healthcare system disruptions. More information about the risks and uncertainties faced by the Company is contained under the caption "Risk Factors" included in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, and the Company's subsequent periodic reports filed with the SEC. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.

Front Cover: Phoebe, Analyst at North Creek Quality Control Laboratory

Seagen is a Global Oncology Company Focused on Improving Lives of People With Cancer Through Innovative Targeted Therapies

Maximizing Potential of Commercial Portfolio

- **4 FDA-approved first-in-class or best-in-class products**, driven by expanded commercialization engine
- **Broad clinical development programs underway** to support potential label expansions

Advancing Deep & Diverse Pipeline

- **13+ clinical-stage programs** maximize pipeline opportunity
- **The leader in ADC technology,** with R&D expertise in empowered antibodies for targeted cancer therapy

Well-Positioned for Future Innovation & Growth

- **Financial strength** with >$1B YTD revenue[1], $2.4B in cash and investments[2]
- **Expanded geographic footprint**, active corporate development and 50+ strategic partnerships
- **>$1B in annual R&D investment**[3]

[1] Year-to-date total revenue ending September 30, 2021; [2] As of September 30, 2021; [3] Based on updated FY21 financial guidance provided on October 28, 2021

2021 Accomplishments and Milestones Lay Foundation for Continued Progress

Maximizing Potential of Approved Portfolio

PADCEV®
- **Full FDA approval** in post-platinum/CPI mUC and additional cisplatin-ineligible 2L indication
- **Regulatory approvals** in Canada and Japan; positive CHMP opinion in Europe
- **EV-103 trial Cohort K** enrollment complete

TUKYSA®
- **Regulatory approvals** in the EU, Canada and UK
- **MOUNTAINEER CRC trial** enrollment complete

TIVDAK®
- **Accelerated FDA approval** in 2L cervical cancer
- **Global randomized trial initiated** in 2L cervical cancer
- **Combo data in cervical cancer** presented at ESMO

ADCETRIS®
- **ECHELON-1 HL** 5-year data published

Advancing Deep and Diverse Pipeline

- **Disitamab vedotin** late-stage asset in-licensed
- **Ladiratuzumab vedotin** weekly data presented at ESMO
- **SGN-STNV** phase 1 trial initiated
- **Novel ADCs SGN-PDL1V and SGN-B7H4V** trials active; SGN-ALPV IND submitted
- **SEA-CD40** phase 2 basket study initiated
- **SEA-BCMA** initial phase 1 data presented at ASH

Seagen®

CPI: checkpoint inhibitor; mUC: metastatic urothelial cancer; CRC: colorectal cancer; HL: Hodgkin lymphoma; IND: Investigational New Drug application


MAXIMIZING POTENTIAL
OF COMMERCIAL PORTFOLIO

Multi-Product Portfolio with Established and Expanded Commercial Infrastructure

Foundation of care for CD30-expressing lymphomas

ADCETRIS®
brentuximab vedotin | for injection

100k+

patients treated to date across portfolio with growth fueled by expanded commercialization engine scaled for future launches

TUKYSA®
tucatinib
50 mg | 150 mg tablets

Best-in-class TKI for HER2+ breast cancer

First-in-class ADC for urothelial cancer

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

tivdak®
tisotumab vedotin-tftv
for injection 40 mg

First-in-class ADC for cervical cancer

TKI: tyrosine kinase inhibitor

ADCETRIS Regimens are a U.S. Standard of Care in Frontline Hodgkin Lymphoma and Peripheral T-Cell Lymphoma

ADCETRIS® brentuximab vedotin | for injection

- **Commercially available in >75 countries** with Seagen commercializing in U.S. and Canada, and Takeda rest of world
- **Working to maximize usage across six indications** in Hodgkin lymphoma and peripheral T-cell lymphoma while seeking to expand into new indications

Collaboration with Takeda ONCOLOGY

ECHELON-1 Progression-Free Survival Through 5 years



ADCETRIS+AVD continues to demonstrate robust and durable benefit across patients, independent of stage, risk factor or PET2 status[1]

Refer to ADCETRIS USPI for complete safety information, including a **BOXED WARNING for Progressive Multifocal Leukoencephalopathy** and a contraindication for concomitant use with bleomycin due to pulmonary toxicity

[1] Straus, *et.al.*; Lancet Haematology, 2020; AVD: doxorubicin, vinblastine, and dacarbazine

Maximizing ADCETRIS' Future Potential Across Multiple CD30-Expressing Lymphomas and Other Settings

	Trial / Indication	Details	Phase	Status
HODGKIN LYMPHOMA	**HL**	**Frontline:** combination with nivolumab and AD (AN+AD); Stage 3/4 data reported at ASH; Stage 1/2 patients enrolling	Phase 2	Enrolling
	CHECKMATE 744	**Relapsed/Refractory HL:** combination with nivolumab	Phase 2	
	HL	**Retreatment:** monotherapy	Phase 2*	
NON-HODGKIN LYMPHOMA	**ECHELON-3**	**Relapsed/Refractory DLBCL:** combination with rituximab and lenalidomide	Phase 3*	
	PTCL, <10% CD30 expression	**Frontline:** combination with CHP	Phase 2*	
	PTCL	**Retreatment:** monotherapy	Phase 2*	
OTHER SETTINGS	**Post PD-1**	**Relapsed/ refractory solid tumors:** combination with pembrolizumab	Phase 2	
	Non-cancer	**HIV:** monotherapy	Phase 1	Planned

* Registrational intent; AN: ADCETRIS and nivolumab, AD: doxorubicin and dacarbazine, PTCL: peripheral T-cell lymphoma, CHP: cyclophosphamide, doxorubicin, and prednisone

ADCETRIS Combination Has Potential to Optimize Treatment in Frontline Advanced Hodgkin Lymphoma

Response to ADCETRIS + Nivolumab + AD at EOT



1 patient who achieved CR after data cutoff and 1 patient who discontinued AN+AD prior to EOT assessment are not included.
Patient with PD and significant reduction in SPD had new lesions at EOT.

Preliminary results in Stage III/IV patients show promising activity with AN+AD, with an ORR of 93% and a CR rate of 88%[1]

- **Open-label Phase 2 studying ADCETRIS + nivolumab (AN) in combination with doxorubicin and dacarbazine (AD)** in frontline advanced Hodgkin lymphoma
- **No patients discontinued due to peripheral neuropathy**, and 3 of 4 patients that discontinued therapy due to AEs achieved a complete response (CR)
- **Study continues to enroll Stage I/II patients**

Refer to ADCETRIS USPI for complete safety information

[1] Lee, *et al.*, ASH 2021; abstract No. 2454; EOT: end of treatment; SPD: sum of the products of the longest perpendicular diameters; The safety and efficacy of these agents in this setting has been established. Future regulatory approval or commercial availability is not guaranteed.

PADCEV is a First-in-Class ADC for Metastatic Urothelial Cancer and a U.S. Standard of Care in Post-Platinum/CPI Treatment Setting

PADCEV®
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

- **Now approved in the U.S., Canada, Switzerland, Israel and Japan**
- **Promoting to expanded indication** in U.S. in 2L cisplatin-ineligible patients
- **Positive CHMP opinion in Europe**; potential approval in 1Q22; marketing applications in additional geographies planned or under review

Collaboration with astellas

EV-301 Phase 3 Median Overall Survival



PADCEV demonstrated a median OS of 12.88 months compared to chemotherapy at 8.97 months; HR: 0.70 (95% CI: 0.56, 0.89), p=0.00142[1]

Refer to PADCEV USPI for complete safety information, including a **BOXED WARNING for Serious Skin Reactions**

[1] Powles *et al*, ASCO GU 2021; CHMP: Committee for Medicinal Products for Human Use

Broad Urothelial Cancer Development Program to Maximize PADCEV's Future Potential

	Trial	Details	Phase	Status
MONOTHERAPY	**EV-301**	**Global mUC following platinum and PD(L)-1**	Phase 3	Approved[1]
	EV-202	**Basket trial:** HR+/HER2- BC, squamous/non-squamous NSCLC, head & neck cancer, gastric/GEJ/esophageal cancer	Phase 2	Enrolling
	EV-104	**NMIBC:** intravesical administration	Phase 1	
COMBINATION WITH PEMBROLIZUMAB	**EV-103 Cohort K**	**1L mUC cis-ineligible**	Phase 2*	Enrolled
	EV-302	**Global 1L mUC cis-eligible and cis-ineligible**	Phase 3*	Enrolling
	EV-303 & EV-304	**MIBC cis-eligible and cis-ineligible**	Phase 3*	

* Registrational intent; [1] Approved in the U.S., Canada, Switzerland and Japan, and positive CHMP opinion in Europe; BC: breast cancer, NSCLC: non-small cell lung cancer, GEJ: gastroesophageal junction adenocarcinoma, NMIBC: non-muscle invasive bladder cancer, MIBC: muscle-invasive bladder cancer

Initial Compelling Data Support Ongoing Registrational Trials for PADCEV in First-Line Metastatic Setting

EV-103 Cohort A – PADCEV + Keytruda in 1L mUC



Median DOR of 25.6 months, with a median follow-up of 20 months[1]

Refer to PADCEV USPI for complete safety information

- **EV-103 Cohort K** in 1L mUC cis-ineligible patients completed enrollment; data expected in 2H22 **could provide U.S. accelerated approval pathway**
- **EV-302 Phase 3 trial in 1L mUC** regardless of platinum eligibility enrollment ongoing and expected to complete in 2022; **potential to support global submissions**

[1] Friedlander *et al*., ASCO 2021, Poster No. 4528; exploratory data; The safety and efficacy of these agents in this setting has not been established. Future regulatory approval or commercial availability is not guaranteed.

TUKYSA is Best-in-Class Tyrosine Kinase Inhibitor for HER2-Positive Breast Cancer

TUKYSA® tucatinib
50 mg | 150 mg tablets

- Strong adoption of important and valued product across community and academic settings driven by broad label and OS advantage for patients with brain mets in HER2CLIMB
- Approved in 36 countries, with Seagen responsible for U.S., Canada and Europe commercialization, and Merck responsible in rest of world

Regional collaboration with MERCK

Longer-Term Survival Data for Patients with HER2+ Metastatic Breast Cancer and Brain Mets in HER2CLIMB[1]



	Events/Total	HR (95% CI)	P-value	Median OS (95% CI)
TUC+Tras+Cape	118/198	0.600 (0.444, 0.811)	0.00078	21.6 months (18.1, 28.5)
Pbo+Tras+Cape	71/93			12.5 months (11.2, 16.9)

Median OS 9.1 months longer in TUKYSA arm compared with control arm in all brain met patients

With 15.6 months of additional follow-up, TUKYSA regimen resulted in robust and durable OS prolongation

Refer to TUKYSA USPI for complete safety information, including **WARNINGS AND PRECAUTIONS** for diarrhea, hepatotoxicity, and embryo-fetal toxicity

[1] Lin *et al.*, SABCS 2021, Abstract 858

TUKYSA Development Program Encompasses HER2+ Breast, GI and Other Cancers

	Trial	Details	Phase	Status
BREAST CANCER	**HER2CLIMB**	**MBC; 1 or more prior HER2 regimen:** combination with capecitabine and trastuzumab	Phase 2	Approved[1]
	HER2CLIMB-02	**MBC; prior taxane and trastuzumab:** combination with T-DM1	Phase 3*	Enrolling
	CompassHER2 RD	**Adjuvant, high risk of relapse:** combination with T-DM1	Phase 3*	
	HER2CLIMB-05	**1L maintenance:** combination with trastuzumab and pertuzumab	Phase 3*	
	HER2CLIMB-04	**MBC; 2 or more prior HER2 regimens:** combination with trastuzumab deruxtecan	Phase 2	
GI CANCERS	**MOUNTAINEER**	**Metastatic colorectal cancer:** combination with trastuzumab	Phase 2*	Enrolled
	MOUNTAINEER-02	**Metastatic gastric or GEC:** combination with trastuzumab, ramucirumab and paclitaxel	Phase 2/3*	Enrolling
OTHER TUMORS	**Solid tumor basket study**	**Metastatic with HER2 alterations:** combination with trastuzumab	Phase 2	Enrolling

* Registrational intent; [1] Approved in the U.S. and 35 other countries; MBC: metastatic breast cancer; T-DM1: trastuzumab emtansine, GEC: gastroesophageal cancer

Opportunity to Advance TUKYSA to the Frontline Maintenance Setting for Advanced HER2-Positive Breast Cancer Patients

- **HER2CLIMB-05 aims to improve upon the current standard of care**, which is taxane, trastuzumab and pertuzumab, followed by trastuzumab and pertuzumab, as established by the CLEOPATRA study[1]
- **Randomized, double-blind, Phase 3 study of TUKYSA** or placebo in combination with standard of care frontline trastuzumab and pertuzumab as maintenance therapy for advanced HER2+ breast cancer
- **The CNS is a potential first site of distant disease relapse in this population**, thus the addition of an agent with both systemic and CNS activity to the frontline may be optimal
- **Adding TUKYSA to frontline maintenance has the potential to prolong PFS of the current standard-of-care**, dual-mAb regimen

[1] Swain, S., *et al*., Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer, NEJM, 2015; CNS: central nervous system

TIVDAK First and Only U.S. Approved ADC for Recurrent or Metastatic Cervical Cancer with Disease Progression on or After Chemotherapy

tivdak®
tisotumab vedotin-tftv
for injection 40 mg

- **Important yet modest initial opportunity**
  - ~2,000 U.S. patients in 2L setting with treatment options including CPIs, chemotherapy and now TIVDAK
- **Well-positioned to address significant unmet need** in recurrent or metastatic cervical cancer

Collaboration with Genmab

innovaTV 205 Combination Data Presented at ESMO 2021[1]

Parameters	1L TV + carbo (N=33)	2L/3L TV + pembro (N=34)
Confirmed response rate, n (%)	**18 (55)**	**13 (38)**
Complete response, n (%)	4 (12)	2 (6)
Partial response, n (%)	14 (42)	11 (32)
Median duration of response, months	8.3	13.8

1L TV+carbo and 2L/3L TV+pembro showed encouraging and durable antitumor activity

Refer to TIVDAK USPI for complete safety information

[1] Vergote I., *et al*., Tisotumab Vedotin + Carboplatin in First-Line or + Pembrolizumab in Previously Treated Recurrent/Metastatic Cervical Cancer: Interim Results of ENGOT-Cx8/GOG-3024/innovaTV 205, 2021, exploratory data; The safety and efficacy of this agent in this setting has not been established. Future regulatory approval or commercial availability is not guaranteed; TV: tisotumab vedotin

TIVDAK Being Developed in Cervical Cancer as a Single Agent and in Combination with Other Agents

	Trial	Details	Phase	Status
2L+ SETTING	**innovaTV 204**	**Recurrent or metastatic with disease progression on or after chemotherapy:** monotherapy	Phase 2	Approved[1]
	innovaTV 301	**Global recurrent or metastatic with disease progression on or after chemotherapy:** monotherapy	Phase 3*	Enrolling
1L SETTING	**innovaTV 205**	**Recurrent or metastatic:** combination with carboplatin or pembrolizumab	Phase 1/2	

Additional ongoing phase 2 trials evaluating TIVDAK in other solid tumors, including colorectal cancer, NSCLC, pancreatic cancer, head and neck cancer, and ovarian cancer

* Registrational intent; [1] FDA accelerated approval; continued approval may be contingent on verification and confirmation of clinical benefit in confirmatory trials


ADVANCING A DEEP
& DIVERSE PIPELINE

Advancing Disitamab Vedotin in HER2-Expressing Breast, Bladder, Gastric and Other Cancers

- **Novel, high-affinity antibody with blockade of HER2 signaling and enhanced internalization** when compared to trastuzumab, an important characteristic for an ADC
- **Late-stage asset leverages Seagen's vedotin-based drug-linker technology and expertise**; data suggest vedotin-based ADCs combine well with checkpoint inhibitors[1]

Breast cancer	**Bladder cancer**	**Gastric cancer**
Encouraging monotherapy data in HER2 low breast cancer	U.S. BTD designation for bladder cancer	Conditional China approval for gastric cancer; U.S. plan under development

Broad Clinical Development Program

Trial	Phase	Status
2L+ mUC: monotherapy for potential accelerated approval	Phase 2	Active
1L mUC: combination with anti-PD1	Phase 2 & 3	Planned
1L HER2 low breast cancer	Phase 3	Planned
Additional trials planned in gastric cancer and other solid tumors		

[1] Zhou, *et al*, ASCO 2021, Abstract No. 4534 - data demonstrated 94% ORR for DV+anti-PD1 in 1L/2L mUC patients.
BTD: Breakthrough Therapy Designation.

Advancing Ladiratuzumab Vedotin for LIV-1 Expressing Solid Tumors

- **Encouraging single-agent and KEYTRUDA combination data** in metastatic triple-negative breast cancer (mTNBC)
- **Clinical development focused on optimizing dose and schedule** as monotherapy and in combination with KEYTRUDA
- **Basket trial enrolling additional solid tumors** including lung, head and neck, prostate, esophageal, gastroesophageal and melanoma

In collaboration with: MERCK

Maximum Change in mTNBC Tumor Burden

2L LV Q1w Monotherapy[1]



1L LV Q3w + Keytruda[2]



[1] Tsai, ESMO 2021, presentation 259P; [2] Han, *et al.* SABCS 2019, Abstract No. 151

Four Empowered Antibody Early-Stage Programs, Driven by Seagen Proprietary SEA Technology

- **Sugar-Engineered Antibody (SEA) technology is broadly applicable in the generation of non-fucosylated antibodies**, using a small molecule inhibitor added to existing mAb-producing cells
- **Non-fucosylated antibodies enhance engagement with the activating FcγRIIIa receptor** and have minimal binding to inhibitory FcγRIIb receptor
  - Increased affinity for activating FcγRIIIa receptor results in amplified killing of antigen positive cells
  - Preferential enhancement of activating FcγRIIIa binding amplifies immune cell activation

Programs and Development Focus

SEA-TGT	SEA-BCMA	SEA-CD40	SEA-CD70
Enhanced immune agonism/ADCC	Enhanced ADCC	Enhanced immune agonism/ADCC	Enhanced ADCC
Solid tumors and lymphomas[1]	Multiple myeloma[1]	Pancreatic cancer[1] Solid tumors[2]	AML and MDS[1]

[1] Phase 1; [2] Phase 2 basket trial in melanoma and NSCLC; ADCC: antibody-dependent cellular toxicity; AML: acute myeloid leukemia; MDS: myelodysplastic syndrome

Advancing 18 Programs Leveraging Two Technology Platforms Across Solid Tumors and Hematological Malignancies

SEA / Immuno-Oncology Platform

- SEA-CD40
- SEA-TGT
- SEA-BCMA
- SEA-CD70
- Undisclosed IO Program

ADC Technology Platform

- SGN-CD228A
- SGN-B6A
- SGN-STNV
- SGN-PDL1V
- SGN-B7H4V
- SGN-ALPV
- Novel ADC Programs
- Disitamab Vedotin
- Ladiratuzumab Vedotin

Approved Products

Early-Stage Pipeline | **Late-Stage Pipeline** | **Commercial Portfolio**


WELL-POSITIONED FOR
FUTURE INNOVATION & GROWTH

Growing Top Line and Robust Balance Sheet Provides Financial Strength and Enables Investment to Drive Future Innovation

>$1B
in YTD total revenue[1]

$2.4B
in cash and investments[2]

>$1.2B
in annual R&D investments[3]

Q4 and FY 2021 Earnings Call on February 9, 2022

YTD Net Products Sales Exceeded $1 Billion[1], Driven by Growth Across Portfolio



[1] Year-to-date total revenue ending September 30, 2021; [2] As of September 30, 2021; [3] Based on updated FY21 financial guidance provided on October 28, 2021

Corporate Development Approach, 50+ Strategic Partnerships and Expanded Geographic Footprint Empower Global Patient Reach

Technology Licensing and Clinical Trial Supply Agreement Highlights	Commercialization and Co-Development Partnership Highlights

Genentech — A Member of the Roche Group
gsk
MERCK
Pfizer
abbvie
+ Others

Seagen

astellas
MERCK
Genmab
Takeda ONCOLOGY
RemeGen
+ Others

Corporate development approach assesses oncology companies, programs and technologies with a focus on first- and best-in-class targeted therapies to further augment pipeline and capabilities

Global footprint with presence across North America and Europe with partners extending global reach

2022 Anticipated Milestones and Catalysts

ADCETRIS® brentuximab vedotin | for injection

- **Report ECHELON-1 OS data** in frontline HL
- **Report initial solid tumor data** in combination with pembrolizumab
- **Initiate HIV trial in 1Q22**

PADCEV® enfortumab vedotin-ejfv Injection for IV infusion 20 mg & 30 mg vials

- **Expect EMA approval in 1Q22** with other global marketing applications planned or under review
- **Report EV-103 Cohort K data in 2H22**
- **Complete enrollment of EV-302**
- **Report initial EV-103 Cohort H neoadjuvant MIBC data**
- **Report initial EV-202 basket study data**

tivdak® tisotumab vedotin-tftv for injection 40 mg

- **Report additional combination data** in earlier lines of cervical cancer
- **Report initial innovaTV-207 basket study data**

TUKYSA® tucatinib 50 mg | 150 mg tablets

- **Launch in additional European countries**
- **Report MOUNTAINEER data in 2H22**
- **Complete enrollment of HER2CLIMB-02**
- **Initiate HER2CLIMB-05 1L maintenance trial**

Pipeline Programs

- **Initiate DV monotherapy and combination studies**
- **Evaluate potential LV frontline combination approaches with Keytruda**
- **Report data from multiple Phase 1 programs,** including SEA-CD40, SEA-BCMA, and SGN-B6A
- **Initiate Phase 1 studies** including SGN-PDL1V, SGN-B7H4V, SGN-ALPV

EMA: European Medicines Agency

Seagen's Key 2022 Priorities

Maximize potential of 4 approved medicines through clinical development and commercial infrastructure

Advance deep and diverse pipeline to maximize opportunity and develop future drugs 5, 6 and 7+

Leverage ADC leadership and R&D expertise to drive further innovation and growth


Seagen®